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Abstract
One of the most common ways researchers compare survival outcomes across
treatments when confounding is present is using Cox regression. This model is lim-
ited by its underlying assumption of proportional hazards; in some cases, substantial
violations may occur. Here we present and compare approaches which attempt to
address this issue, including Cox models with time-varying hazard ratios; paramet-
ric accelerated failure time models; Kaplan-Meier curves; and pseudo-observations.
To adjust for differences between treatment groups, we use Inverse Probability of
Treatment Weighting based on the propensity score. We examine clinically mean-
ingful outcome measures that can be computed and directly compared across each
method, namely, survival probability at time T , median survival, and restricted
mean survival. We conduct simulation studies under a range of scenarios, and de-
termine the biases, coverages, and standard errors of the Average Treatment Effects
for each method. We then apply these approaches to two published observational
studies of survival after cancer treatment. The first examines chemotherapy in sar-
coma, where survival is very similar initially, but after two years the chemotherapy
group shows a benefit. The other study is a comparison of surgical techniques for
kidney cancer, where survival differences are attenuated over time.
1 Introduction
Many health care studies use observational databases to compare censored survival
times between different treatment or exposure groups. A common statistical ap-
proach used to model such data is the Cox proportional hazards regression model.
However, the standard Cox model makes a strong assumption that the hazards
are proportional between treatment groups of interest over the course of follow-up.
This assumption may not hold in real-world studies.
Survival times are proportional between two groups when the ratio of their haz-
ards is constant over time. [20] Although Cox regression is often used to model sur-
vival times, particularly when adjusting for covariates, there are a variety of models
for censored outcomes which do not rely on the assumption of proportional hazards.
Non-parametric methods, including the ubiquitous Kaplan-Meier method, by defini-
tion do not make assumptions about the functional form of the survival curves, and
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therefore accommodate non-proportionality. [19] An alternative non-parametric
method is the Nelson-Aalen estimator, [11] and a recent method proposes us-
ing pseudo-observations, which can also be used without parametric assumptions.
[2, 3, 1] However, standard implementations of non-parametric approaches do not
readily incorporate covariates. This motivates use of regression-based parametric
and semi-parametric approaches which accommodate non-proportionality. The Cox
model can be modified to include time dependent hazards, relaxing the assumption
of proportionality. [11] Accelerated Failure Time (AFT) models are a different class
of regression methods for censored data, which assume a linear model for log-time.
They are often modeled fully parametrically, and for many choices of distribution
for the error term, the models are non-proportional. Semi-parametric AFT meth-
ods are also available. [18] Proportional odds models can also be used in the setting
of non-proportionality. [11]
Given the number of choices, a natural question is which method performs best
in real-world conditions, particularly when analyzing observational data where con-
founding is an issue. In this paper, we focus on approaches which can use propensity
score weighting to address confounding. The propensity score is commonly used in
the analysis of clinical studies and has many advantages as we discuss in detail in
section 2. We then describe several methods for analysis of survival data where the
proportional hazards assumption is violated. We focus on meaningful estimands
and compare the performance of parametric, semi-parametric, and nonparamet-
ric approaches; some of which are commonly used while others are less familiar.
We focus on methods which can 1) be used with Inverse Probability of Treatment
Weighting (IPTW), 2) identify the estimands of interest, and 3) are readily imple-
mented using currently available software. We provide insight on the performance
of these methods in scenarios often involved in clinical studies.
This work is motivated by two of our recently published studies in cancer in
which the treatment effect exhibited non-proportional hazards. In our study of
chemotherapy for soft-tissue sarcoma, there was a negligible survival benefit until
about two years after the start of treatment. [25] In another study comparing
two different surgical techniques in early-stage renal cancer, we found that one
approach had a strong benefit immediately after surgery, but the benefit decreased
over time. [27] The data for both of these studies came from an observational
source, the National Cancer Database. [9] Therefore, both were likely subject to
confounding by indication; that is, the choice of treatment is informed by factors
that are also associated with survival.
The outline of our paper is as follows. In section 2, we provide a brief review of
estimating the average treatment effect using propensity score weighting. In section
3, we present several methods to analyze survival outcomes under non proportional
hazards that utilize IPTW. In section 4, we conduct extensive simulation studies
to compare the methods presented in section 3. In section 5, we use our motivating
studies of soft-tissue sarcoma and renal cancer to demonstrate implementation and
interpretation of the various methods described earlier. We conclude with a brief
discussion and thoughts on next steps.
2 Propensity Score weighting
The propensity score, first proposed by Rosenbaum and Rubin, [29, 30] is defined
as the probability of receiving treatment given a set of covariates,
e = P (Z = 1 | X)
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where e is the propensity score, Z is a binary indicator for treatment and X is
a vector of covariates. The propensity score is useful for causal inference, under
the potential outcomes framework. Here, each subject has two potential outcomes
under control and treatment conditions (Y 0, Y 1), one of which is unobserved. [32,
16] The estimand of interest is often the Average Treatment Effect (ATE), defined
as
ATE = E(Y 1 − Y 0),
which is usefully interpreted as the expected value of the outcome if every subject
is given the treatment, compared with the expected value if every subject receives
the control. Strongly ignorable treatment assignment occurs under the conditions
(Y 0, Y 1) ⊥ Z | X and 0 < e < 1,
that is, when the potential outcomes are independent of treatment assignment
conditional on the covariates, and each subject has a nonzero probability of receiving
both the treatment and the control (positivity). When strong ignorability holds,
the ATE based on the propensity score is identifiable from the observed data.
[29, 31, 28]
E(Y 1 − Y 0) = E(Y | Z = 1, e)− E(Y | Z = 0, e).
Propensity score methods have a number of benefits over traditional regression
adjustment. First, they provide an easy way to check for sufficient covariate overlap
and balance between the treated and control groups. [4] Second, one can use flexible
and modern approaches, such as ensemble models, [36] to estimate the propensity
scores, which make the estimates less vulnerable to bias from an incorrect functional
form. Propensity scores also allow for the use of doubly robust methods. [14] Third,
propensity score weighting approaches provide marginal, not conditional, estimates,
which are more interpretable and useful to clinicians and policymakers. [6, 21, 7, 22]
There are several ways to use propensity scores in analyses of survival data.
Here we focus on weighting, specifically inverse probability of treatment weighting
(IPTW). The idea underlying IPTW is to create synthetic samples where covari-
ates are unrelated to treatment assignment. The weighted samples can then be
summarized and compared directly. One nice property of using IPTW is that the
estimand is the ATE. [4] To implement an IPTW analysis, one must first obtain
the estimated propensity scores for each subject (eˆi). This can be accomplished via
a number of approaches, including logistic regression, random forests, or ensemble
methods. The IPTW for subject i is then defined as
wˆi =
Zi
eˆi
+
1− Zi
1− eˆi .
In subsequent analyses, these weights are used to estimate the expected effects
under the treatment and control conditions.
3 Survival methods under non proportional
hazards
3.1 Quantifying differences between groups with non-
proportionality
In the setting of survival outcomes with non-proportionality, we must first decide
what our estimand will be. It should be readily interpretable by the intended au-
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dience, meaningful given the observed data features, and estimable using available
software. If we fit a proportional hazards model to non-proportional data, we would
obtain an estimate of a single HR, but this would be a misleading measure because
it would essentially be a summary of the different hazard ratios at each observed
failure time. Alternative hazard ratios have been proposed including the average
hazard ratio which is interpreted as the average of the hazard ratios weighted by
the number of patients at risk. [34]
The difficulties inherent in reporting hazard ratios in the setting of non-proportionality
can be avoided by focusing on measures that can be defined directly from the sur-
vival functions for the treated and control arms, S1(t) and S0(t), respectively.
The simplest approach compares differences in survival probabilities at a par-
ticular time t = T .
∆St = S1(t = T )− S0(t = T )
Quantiles of the survival functions can also be compared. For instance, if the
survival curves are defined for S(t) = 0.5, median survival times can be compared.
∆T50 = (t : S1(t = T ) = 0.5)− (t : S0(t = T ) = 0.5)
These measures have the benefit of being readily understood by a clinical audience,
but the drawback is that they do not comprehensively measure survival effects over
the length of follow-up. An alternative measure is restricted mean survival (RMS),
the mean survival up through some time T where S(t) is defined (i.e. mean survival
up through the maximum observation time). [12] RMS can be found using the area
under the survival curve, where the difference in RMS between the treated and
control conditions is
∆RMSt =
∫ t
0
S1(T = t)dt−
∫ t
0
S0(T = t)dt.
Each of these measures are estimated directly from the survival curve, so they
are always meaningful regardless of proportionality. However, not every method
for the analysis of survival data explicitly estimates the survival curve, and not
all methods can accommodate weighting. In the subsequent sections, we focus
on methods which can 1) accommodate IPTW, 2) allow the estimation of the
measure of interest (∆ST , ∆T50, and ∆RMST ), and 3) are readily implemented
using published software.
3.2 Cox model
Although the Cox proportional hazards model does rely on the assumption of pro-
portionality, the model tends to be robust to small deviations from this assumption.
However, if n is large, as is common is registry studies, small deviations from pro-
portionality may be statistically significant when tested using standard diagnostic
tests (e.g. Cox-Snell residuals, Schoenfeld residuals). [15] Therefore, the Cox model
may still be useful in some cases were deviations from proportionality are demon-
strated. The Cox model is defined as follows:
hi(t | Zi) = h0(t)exp(βZi).
IPTW can be readily accommodated in the Cox model, by weighting the contribu-
tion of each observation to the partial likelihood function:
L(β) =
N∏
i=1
(
exp(βZi)∑
j∈R(ti) wˆjexp(βZj)
)wˆi
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where R(ti) is the risk set at time ti. The parameter β is the average of the log-
hazard ratios at each failure time. Importantly, one can find Sˆ(t) based on the
estimates hˆ0(t) and βˆ.
We can also extend the standard Cox model, relaxing the assumption of pro-
portionality, by allowing the hazard ratio to vary as a function of time.
hi(t | Zi) = h0(t)exp(βZi + f(Zi, t)).
In our simulations, we consider two particular cases, 1) allowing the hazard to vary
by log-time.
f(Zi, t) = κZilog(t),
and 2) using a piecewise constant treatment effect
f(Zi, t) =

0 0 ≤ t < C1
κ1Zi C1 ≤ t < C2
κ2Zi C2 ≤ t
These models can all be implemented with the widely-used survival package in
R. [35]
3.3 Parametric AFT models
Accelerated Failure Time (AFT) models assume a linear model for log(T ). [11, 18,
38]
log(Ti) = µ+ βZi + σi
Here, we consider parametric models, where the error term  is assumed to take on
a given distribution. We have many choices for the distribution of . A common
choice is the Gumbel distribution, which yields a Weibull hazard model; however,
the Weibull model is also a proportional hazards model. We can allow for non-
proportionality by allowing the hazard ratio to change over time
hi(t | Z) = exp[−(βZi + f(Zi, t))]γλγtγ−1, (1)
where λ is the scale and γ is the shape parameter. If we let
f(Zi, t) = κZilog(t),
then (1) can be re-written as
log(Ti) =
1
γ + κZi
(−log(λ) + βZi + i) .
i ∼ Gumbel
Therefore, if we include an additional parameter in the Weibull model, where the
shape can vary by treatment, the model specification allows the hazard ratio to
vary by log-time.
Another flexible alternative is the generalized gamma model, which is also a
three parameter model. [23] The distribution of the errors has an additional pa-
rameter Q.
log(Ti) = µ+ βZi + σi
i ∼
( |Q|
Γ(1/Q2
)(
exp(Qv)
Q2
)1/Q2
exp
(−exp(Qv)
Q2
)
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This model encompasses other distributions as special cases; when Q = 1 we
have a Weibull AFT model, and if Q = 0 it results in a log-normal model.
For any AFT model, the weights wˆi can be applied during estimation of pa-
rameters. Here, we focus on the 3-parameter Weibull and generalized gamma AFT
models, but a wide range of AFT models can be fit in R using the flexsurv package.
[17]
3.4 Kaplan-Meier method
Another strategy is to avoid parametric assumptions entirely, and use Kaplan-Meier
curves with IPTW to directly estimate the survival functions. [10, 39]
Sˆ(t) =
∏
tj≤t
(
1− d̂
w
j
n̂wj
)
Where d̂wj =
∑
i:Ti=tj
wˆiδi is the weighted number of events and n̂wj
∑
i:Ti≥tj wˆi
is the weighted number of people at risk at time tj . Weighted curves are easily
estimated in R via the survival package.
3.5 Pseudo-observations
Another non-parametric method which can be used to estimate the survival curve is
the recently-developed pseudo-observations approach. [2, 3, 1] This framework uses
a missing data approach to account for censoring. If no missing data or confounders
are present, the ATE can be found using a simple average over the (possibly trans-
formed) outcomes for each subject
θ = E(f(Y )) =
1
n
∑
i
f(Yi).
But if f(Yi) is unknown for some subjects, we cannot calculate E(f(y)) directly.
Instead, we can define the pseudo-observation for subject i as
θˆi = nθˆ − (n− 1)θˆ−i
where θˆ is a consistent estimate for θ, and θˆ−i is the estimator applied to all
observations excluding subject i. The pseudo-observations are then used in place
of all observations, not only the ones which are missing due to censoring.
In a survival context, our outcome of interest, θ, is the probability of survival at
time t, and θi is a binary indicator for the status (alive/dead) of subject i at time
t. We can use a non-parametric method, such as Kaplan-Meier, to estimate SZ(t),
which is then used to find θi for all observations in arm Z.
θˆZi = nZ SˆZ(t)− (nZ − 1)SˆZ(t)−i
Heuristically, nZ Sˆ(t) is the expected number of patients alive at time t, and (nZ −
1)Sˆ(t)−i is the expected number of patients other than patient i alive at time t. θˆi
is used in place of (possibly unobserved) survival status at time t. Therefore, the
probability of being alive at time t in arm Z is
Pˆ(Y |Z, t) = 1
nZ
∑
i
θˆZi.
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Incorporating propensity-score weights to account for confounding is straight-
forward.
Pˆ(Y |Z, t) = 1
nZ
∑
i
wˆiθˆZi
There are several benefits of using the pseudo-observations approach. It has been
demonstrated to provide a valid estimate of the ATE in a causal framework, and
requires weaker assumptions than regression-based models. It also supports estima-
tion of many outcomes of interest. We can estimate Pˆ(Y |Z, t) at each failure time,
defining the survival curve, which in turn allows us to estimate the measures of
interest described in section 3.1. Pseudo-observations can also be used to estimate
RMS. This method can be implemented using the R package pseudo. [26]
3.6 Variance estimation
To conduct inference for the outcomes of interest, we need to quantify uncertainty.
Some methods have closed-form variance estimators for our estimands of interest,
but others do not. This motivates the use of a non-parametric bootstrap to estimate
variances and find confidence intervals.[13] Bootstrap-based estimates are available
for every combination of model and outcome we discuss above. Further, to correctly
account for the variance of eˆ, the estimated propensity scores, we can re-estimate
the propensity score within each bootstrap iteration. [5]
4 Simulation Studies
4.1 Simulation Methods
We tested the performance of the methods described above using simulation stud-
ies. We assessed the bias, coverage, and variance of each method’s estimates of our
outcomes of interest: median survival, restricted mean survival, and survival prob-
ability at time T . We based our covariate and outcome distributions, and effect
sizes on our NCDB cancer studies to mimic real world scenarios.
First, we simulated a set of covariates based on the observed multivariate distri-
bution of the NCDB covariates in the renal dataset. We used the R package genOrd
[8] to draw variables representing gender, age, stage, histology, tumor grade, Charl-
son comorbidity score, race, ethnicity, insurance status, facility type, income, and
education. As our goal here is to evaluate the survival analysis methods, and not
the propensity score estimation methods, we held this set of covariates constant
for each simulation; we employ simulated covariates instead of the actual covari-
ates so that our data and simulation code can be shared. (Available online at
https://github.com/BethHandorf/NonPH_IPTW)
We used a simple logistic model with linear covariate effects to determine each
subjects’ probability of being assigned to the treatment condition (versus control).
The effect size (log-scale) for each covariate ranged from 0.8 (effect of high vs low
stage) to 0.03 (for each additional year of age). This corresponds roughly to the
effect sizes estimated when modeling actual treatment allocation in the NCDB
sample. This model defined the probability that each individual would be allo-
cated to the treatment condition. We set the intercept such that, on average, the
population’s probability of receiving the treatment was 0.5.
Survival times were drawn based on a Weibull model with a time-varying treat-
ment effect.
h(t) = γλtγ−1exp(β1Z + f(Z, t) +Xψ) (2)
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In our base case, the hazard ratio varied by log time f(Z, t) = β2Zlog(t), we set β1 =
-0.69, β2 = 0.25, with a sample size of 5000 total cases. For each individual, survival
times under Z = 1 and Z = 0 were both drawn using the R package simsurv.
[33] These true potential outcomes were used to calculate the true ATE for the
estimands of interest. Observed treatment status was drawn from the binomial
based on each individuals probability of receiving the treatment, as defined by our
propensity score model.
For each set of simulated outcomes, we first estimated the propensity scores
using a logistic regression model, and then calculated respective IPTWs for each
individual. Using these estimated weights, we fit each of the models described
above in Section 3 using standard R packages, including flexsurv for parametric
survival models and pseudo for pseudo-observations methods.
We repeated this simulation framework with various changes to Equation 2, for
a total of five scenarios:
1. Base case: β1 = -0.69 ; f(Z, t) = 0.25Zlog(t)
2. Piecewise constant (PWC) hazard ratio: β1 = 0; f(Z, t) = −0.25ZI(t ≥ 2),
where I(·) is the indicator function
3. Modest non-proportionality β1 = -0.69 ; f(Z, t) = 0.125Zlog(t)
4. Modest treatment effect β1 = -0.41 ; f(Z, t) = 0.25Zlog(t)
5. Base case, with a smaller sample size (N=500 per arm)
Senario 1 (base case) had a large treatment effect with substantial non-proportionality.
Scenarios 2-4 were chosen to approximate the parameters and non-proportionality
found in the clinical examples, and scenario 5 was used to assess how the methods
perform with a more modest sample size.
4.2 Simulation Results
For each method, we assessed performance based on the mean bias, standard error,
and coverage for the ATE for treatment verusus the control. For the base case, the
bias was often largest for the standard Cox model, as expected given the substantial
degree of non-proportionality in the simulated data. Bias in the Cox model tended
to be larger (relative to that of other methods) for the point estimates of survival.
The generalized gamma AFT model also had large bias relative to other methods;
at 10 years, it’s bias was actually greater than that of the Cox model. Even though
this three-parameter model is flexible and allows for non-proportionality, fitting this
mis-specified parametric model still introduced substantial biases into the results,
comparable in size to those found using the standard Cox model. In the base case,
the Cox model with a treatment effect varying by log-time was correctly specified,
but to our surprise, it was often outperformed by the piecewise constant time-
varying Cox model. The fully parametric AFT model with variable location and
scale parameters was also correctly specified, and it had comparable bias to that
of the time-varying Cox models. The non-parametric Kaplan-Meier and pseudo-
observation methods generally had the lowest bias. Finally, we note that the RMS
was less sensitive to the choice of method than the other outcomes of interest; the
relative differences in the sizes of the biases were smallest for this survival outcome.
(see Figure 1)
As shown in Table 1, coverage was worst for the standard Cox model, followed
by the generalized gamma AFT model. The time-varying Cox models did better,
although coverage was surprisingly low for the log-time model at the 2-year outcome
8
(0.82). Coverage for the non-parametric methods was close to the nominal level
for all outcomes. Standard Errors (SEs) of the differences in treatment effects were
usually slightly larger for the non-parametric methods than for the parametric and
semi-parametric methods. (See Appendix Figure 1) Comparing the SEs for the
Kaplan-Meier versus the Weibull model, the increases ranged from 0.3-24.4%, and
were lowest for RMS and highest for 2-year survival.
For piecewise constant hazards (scenario 2), biases were typically lowest for
the non-parametric methods and when using a PWC time-varying Cox model. An
exception to this was for RMS, where the na¨ıve Cox model and Weibull AFT model
had the lowest bias. This likely occurred because bias from different timepoints were
in different directions (positive at 2 and 5 years, negative at 10 years), and may have
cancelled each other out when calculating the area under the survival curve. (Note
that Figure 1 shows the absolute value of the average biases). So, although biases
may have been lower in this simulation for these mis-specified models, such behavior
should not be relied upon in other scenarios. Coverages (See Appendix Table 1)
were close to the nominal when biases were low. Standard errors were generally
similar to be base case, except for median survival, where they were somewhat
larger.
When the effect of non-proportionality was modest (scenario 3), biases tended
to be smaller than those of the base case, especially for estimates of survival prob-
abilities at a given timepoint. When the treatment effect was modest (scenario 4),
results were generally similar to those of the base case. In the small sample size
case (scenario 5), the bias was similar to that of the base case, with the exception
of RMS, where across methods, biases were larger than those of the base case. As
expected, SEs were higher when the sample size was smaller.
Table 1: Coverage for base case
Method 2y 5y 10y Median RMS
Cox 0.00 0.07 0.61 0.81 0.71
CTV LT 0.82 0.91 0.93 0.94 0.93
CTV PWC 0.96 0.96 0.95 0.95 0.93
AFT GG 0.00 0.37 0.44 0.94 0.90
AFT WBL LS 0.89 0.93 0.93 0.95 0.93
Pseudo 0.97 0.97 0.96 0.95 0.94
Wtd KM 0.97 0.96 0.96 0.95 0.94
4.3 Computational resources required
The computational time and resources required to fit each model varied substan-
tially. Depending on the size of the dataset, computational considerations may
become important, especially given our use of the bootstrap to compute confidence
intervals. The fastest method was weighted KM. To fit a Cox model with a time
varying-effect of log-time, we found it infeasibly slow to split the dataset at each
observed failure time given our large sample size. Instead, we limited the splits to
occur at one-month intervals; we tested this approach and found that the results
were nearly identical to those obtained by splitting at each failure time. The pseudo
observations approach was also relatively slow, and highly memory intensive, even
when we estimated S(t) at one-month intervals. Table 2 shows the time required to
fit each model once, and the total time required to calculate 500 bootstrap samples.
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Figure 1: Mean bias (absolute value) in estimates from simulation studies
Cox CTV LT CTV PWC AFT GG AFT WBL LS Pseudo Wtd KM
2 years
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CTV=Cox Time-Varying; LT=Log-Time; PWC=Piece-Wise Constant; AFT=Accelerated Failure Time;
GG=Generalized Gamma; WBL LS= Weibull Location-Scale; Pseudo=Pseudo-Observations; Wtd
KM=Weighted Kaplan-Meier; NHP=Non-Proportional Hazards; TE=Treatment effect; SS=Sample Size
Table 2: Performance comparison: time required for N=5,000
Method Per bootstrap iteration (sec) Total time (min)
Cox 0.98 8.21
CTV LT* 7.60 63.44
CTV PWC 0.41 3.40
AFT GG 13.70 114.39
AFT Weibull LS 5.26 43.90
Pseudo** 2.17 18.14
Wtd KM 0.14 1.18
*28 times higher if split at each failure
**60 times higher if estimated at each failure
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5 Comparative effectiveness of Cancer Ther-
apies
We applied the previously described methods to estimate the effect of treatments on
survival in two clinical studies using the National Cancer Database (NCDB). The
NCDB is a large registry which encompasses approximately 70% of newly diagnosed
cancer cases in the United States. It contains variables describing patient and tumor
characteristics, and the treatments they receive. [9] Here, we describe two studies we
conducted using the NCDB that featured two different forms of non-proportional
hazards. The first is a moderately sized study where two treatment groups had
similar survival initially, but differences in long-term outcomes. The second example
is a much larger study where benefits of one treatment were attenuated over time.
5.1 Sarcoma
Soft-tissue sarcoma is a rare cancer of the connective tissue (e.g. fat, muscle,
blood vessel), usually arising in the extremities. Stage III disease (high grade,
large, or deep tumor) is typically treated surgically or with radiation therapy. It
remains uncertain whether chemotherapy provides an overall survival benefit for
these patients, and its use is optional according to national guidelines. [37] We
studied this question using the NCDB, creating a cohort of Stage III sarcoma
patients (with various histologies) treated with definitive surgical resection of the
primary tumor, with or without chemotherapy pre/post operatively. We identified
5,337 cases with recorded overall survival data, of whom 28% were treated with
chemotherapy. [25]
Due to the non-randomized nature of the data, there were substantial differences
between treatment groups. For example, patients treated with chemotherapy were
younger and had fewer recorded co-morbid conditions. Furthermore, the hazards
for the treatment groups exhibited substantial non-proportionality, as is clearly ev-
ident upon examining the complementary log-log survival curves. (See Figure 2)
Testing the Schoenfeld residuals provides further evidence of non-proportionality
(P=0.047). We used IPTW to account for covariate imbalance between the treat-
ment groups. The propensity score was estimated using all available covariates
(including age, gender, insurance status, income, comorbidity score, tumor histol-
ogy, grade, size, anatomic site, treating facility type, and travel distance.) The
IPTW Kaplan-Meier curves are shown in Figure 2. In our original analysis, we also
fit a time-varying Cox proportional hazards model, assuming a piecewise constant
hazard ratio, which could change at two years. We found that there was little effect
of chemotherapy during the first two years after diagnosis, but that patients treated
with chemotherapy did better in the long term. These results motivated simulation
scenario 2 (PWC).
Here, we apply each of the methods discussed in the sections above to the
sarcoma data. Results for RMS, 2 year survival, and 5 year survival are shown in
Table 3. Median and 10-year survival were not estimable from the observed data, so
we excluded these outcomes. We found that the different methods yielded different
effect size estimates; however, these differences were often modest and in some
cases would not change statistical inferences. For example, ∆RMS varied from a
minimum of 0.409 (AFT with a generalized gamma distribution) to a maximum
of 0.468, but all models showed an improvement in RMS for patients treated with
chemotherapy. In other cases the inferences would differ based on the model chosen.
At 2 years, the standard Cox model showed a difference of 3.6% between the treated
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Figure 2: Survival in stage III sarcoma by chemotherapy
0 20 40 60 80 120
0.
0
0.
4
0.
8
Unadjusted 
Months
No chemo
Chemo
5e−02 5e−01 5e+00 5e+01
−
6
−
4
−
2
0
Complementary log−log
Months
No chemo
Chemo
0 20 40 60 80 100 120
0.
0
0.
4
0.
8
IPTW
Months
Su
rv
iv
a
l
No chemo
Chemo
Table 3: Chemotherapy in sarcoma: results from each model
RMS 2 years 5 years
∆ LCL UCL ∆ LCL UCL ∆ LCL UCL
Cox 0.452 0.146 0.757 0.036 0.013 0.060 0.052 0.018 0.088
TV Cox: log-T 0.457 0.132 0.752 0.018 -0.011 0.043 0.052 0.019 0.087
TV Cox: PWC 0.442 0.117 0.743 -0.003 -0.038 0.028 0.044 0.006 0.081
AFT Gen Gamma 0.409 0.114 0.680 0.039 0.011 0.064 0.047 0.014 0.079
AFT Wbl TV shape 0.468 0.160 0.773 0.026 0.002 0.048 0.054 0.020 0.090
Weighted K-M 0.439 0.109 0.746 -0.007 -0.043 0.026 0.041 0.003 0.078
Pseudo-obs* 0.439 0.110 0.745 -0.007 -0.043 0.026 0.041 0.003 0.078
*Centered weights
∆ = Difference between ATEs for chemo vs no chemo, boldface denotes significance
LCL = Lower confidence limit, UCL = Upper confidence limit
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and control arms, which was statistically significant. The results of both AFT
models also found significantly higher survival in the chemotherapy group. However,
the weighted Kaplan-Meier method showed a non-significant difference of -0.7%.
Both time-varying Cox models and the pseudo-observations method also produced
non-significant differences.
We would like to note that in this data analysis example, we found that the
pseudo-observations method was sensitive to deviations in the mean of the esti-
mated weights from the expected value of 1. This can be explained by both how
the weights are applied and how the survival function is estimated. Each patient’s
(binary) contribution to the survival function is weighted, and the weighted indica-
tors are then averaged. Therefore, if the average weight is not equal to 1, at baseline
the survival function will not start at 1. To address this issue in the estimation of
the survival function when using pseudo-observations, we centered the weights so
their mean was exactly 1. However, we note that this was done heuristically, and
not theoretically driven. Further exploration of this issue is warranted.
5.2 Renal Cancer
The second motivating clinical example for this work was a study of surgical op-
tions for early stage renal cancer. These small tumors can be treated with Radical
Nephrectomy (RN) or Partial Nephrectomy (PN). PN preserves more kidney tissue,
but surgery/recovery is more difficult and it is more likely to be given to healthier
patients. [24, 27] Here, we focus on a subgroup from the original study: patients
aged 51-60 with T1a tumors, which gives a sample size of 28,973 patients (61.1%
treated with PN). In unadjusted analysis, patients given PN had improved survival
over those given RN. However, these results are subject to confounding by indica-
tion. Examination of the complementary log-log plots shows a notable deviation
from non-proportionality, which is confirmed by testing the Schoenfeld residuals
(P<0.0001). [15]
When we fit an IPTW Cox PH model to these data, allowing the hazards to
vary as a function of log-time, such that h(t) = λ0(t)exp(β1Z + β2Zlog(t)) the
maximum likelihood estimates are βˆ1 = −0.468 and βˆ2 = 0.136. Therefore, the non-
proportionality observed here is close to our modest time-varying hazard simulation
scenario (number 3), and the treatment effect is modest as well, similar to what we
used in scenario 4.
Our results were largely simiar, regardless of what model was used. (See Table
4) This was particularly the case for the RMS and five-year survival. Two-year
survival showed the largest range in results, with estimated differences ranging
from 0.9% (Generalized Gamma AFT model) to 1.6% (Cox model with piece-wise
time-varying effects). The standard Cox model gave an estimated difference of
1%, compared to 1.5% from the Kaplan-Meier method. Even with these small
effects, we found that none of the 95% confidence limits crossed zero, so all models
would lead to the same inference: a small benefit for PN over RN. The congruous
inferences were partially driven by the very large sample size, and the resulting
small confidence intervals; however, given the clear evidence of non-proportionality,
it is notable that the point estimates for the standard Cox model were close to
those of time-varying or non-parametric methods.
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Figure 3: Survival in early stage renal cancer by surgery type
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Table 4: Effect of PN vs RN in renal cancer: Results from each model
RMS 2 years 5 years
∆ LCL UCL ∆ LCL UCL ∆ LCL UCL
Cox 0.268 0.199 0.331 0.010 0.007 0.012 0.027 0.020 0.034
TV Cox: log-T 0.267 0.199 0.330 0.014 0.010 0.018 0.029 0.022 0.036
TV Cox: PWC 0.264 0.196 0.327 0.016 0.012 0.020 0.030 0.021 0.037
AFT Gen Gamma 0.263 0.194 0.326 0.009 0.007 0.012 0.026 0.020 0.033
AFT Wbl TV shape 0.264 0.196 0.329 0.019 0.014 0.023 0.031 0.024 0.038
Weighted K-M 0.268 0.200 0.333 0.015 0.011 0.020 0.029 0.020 0.036
Pseudo-obs* 0.269 0.200 0.334 0.015 0.011 0.020 0.029 0.020 0.036
*Centered weights
∆ = Difference between ATEs for PN vs RN, boldface denotes significance
LCL = Lower confidence limit, UCL = Upper confidence limit
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6 Discussion
When analyzing survival outcomes, we often see non-proportional hazards. Based
on our findings, it seems that non-proportionality is readily addressable in practice
with weighted Kaplan-Meier curves, the simplest method we assessed. It performed
quite well across a variety of scenarios and outcome measures of interest. The IPTW
Kaplan-Meier method does not require specialized software or methods, and it also
had the best computational performance. There is a penalty in terms of efficiency,
but we found the increase in the size of the standard errors (compared to parametric
methods) to be small in practice. We believe that the larger standard errors are a
minor drawback when compared to the benefits of fewer assumptions and reduced
bias.
In this work, we used simple IPTW weights. Alternative propensity score
weights have also been proposed; [6] notably, variance stabilized weights have good
properties, especially when one treatment is given to a small proportion of the pa-
tients. In our simulation studies, we used a simple functional form to model the
covariates’ relationship with the probability of receiving treatment. Therefore, the
simple logistic regression model used to estimate the propensity scores was cor-
rectly specified. In practice, there may be much more complex covariate effects,
motivating more flexible procedures to estimate the propensity scores, such as en-
semble machine learning methods. [36] Such methods have been shown to improve
prediction, but are often more resource-intensive to implement.
Our simulation studies were directly informed by the two cancer studies dis-
cussed in Section 5. We sought to better understand how choice of method may
affect results of these real-world analyses, and to learn broader lessons about how
best to accommodate non-proportionality in large, observational studies. Although
both clinical examples had large sample sizes, we found in simulations that the
results held up even when sample sizes were small. Taken together, our simulation
results and clinical examples show that one can easily protect against incorrect
inferences using IPTW Kaplan-Meier curves to estimate treatment effects.
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Figure A1: Mean standard error of estimates from simulation studies
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CTV=Cox Time-Varying; LT=Log-Time; PWC=Piece-Wise Constant; AFT=Accelerated Failure Time;
GG=Generalized Gamma; WBL LS= Weibull Location-Scale; Pseudo=Pseudo-Observations; Wtd
KM=Weighted Kaplan-Meier; NHP=Non-Proportional Hazards; TE=Treatment effect; SS=Sample Size
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Table A1: Coverage probabilities by scenario
Scenario Method 2y 5y 10y Median RMS
PWC Cox 0.00 0.51 0.30 0.96 0.95
PWC CTV LT 0.95 0.78 0.92 0.90 0.84
PWC CTV PWC 0.96 0.96 0.87 0.94 0.90
PWC AFT GG 0.00 0.75 0.10 0.90 0.91
PWC AFT WBL LS 0.03 0.91 0.81 0.92 0.94
PWC Pseudo 0.96 0.95 0.96 0.95 0.91
PWC Wtd KM 0.96 0.95 0.96 0.95 0.92
Modest NPH Cox 0.00 0.45 0.83 0.94 0.79
Modest NPH CTV LT 0.76 0.87 0.94 0.94 0.89
Modest NPH CTV PWC 0.96 0.97 0.96 0.95 0.92
Modest NPH AFT GG 0.13 0.72 0.80 0.95 0.89
Modest NPH AFT WBL LS 0.90 0.91 0.95 0.93 0.92
Modest NPH Pseudo 0.96 0.97 0.96 0.95 0.92
Modest NPH Wtd KM 0.97 0.98 0.97 0.95 0.92
Modest TE Cox 0.00 0.15 0.48 0.49 0.86
Modest TE CTV LT 0.78 0.93 0.92 0.94 0.94
Modest TE CTV PWC 0.94 0.95 0.95 0.96 0.94
Modest TE AFT GG 0.00 0.42 0.35 0.75 0.94
Modest TE AFT WBL LS 0.91 0.95 0.94 0.95 0.95
Modest TE Pseudo 0.96 0.95 0.94 0.95 0.95
Modest TE Wtd KM 0.96 0.95 0.95 0.96 0.95
Small SS Cox 0.02 0.64 0.88 0.93 0.86
Small SS CTV LT 0.93 0.93 0.95 0.97 0.93
Small SS CTV PWC 0.97 0.97 0.95 0.97 0.94
Small SS AFT GG 0.27 0.82 0.82 0.96 0.93
Small SS AFT WBL LS 0.91 0.93 0.95 0.96 0.95
Small SS Pseudo 0.96 0.98 0.96 0.96 0.96
Small SS Wtd KM 0.97 0.97 0.96 0.96 0.95
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